Implantation or Injectable Dosage Form New Animal Drugs; Flunixin Meglumine

الملخص

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Schering-Plough Animal Health Corp. The supplemental NADA provides for veterinary prescription use of flunixin meglumine solution, intravenously, for control of pyrexia associated with bovine respiratory disease and endotoxemia, and control of inflammation in endotoxemia, in beef and nonlactating dairy cattle.